Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480]
Discontinued
Reference number: GID-TA10465
Following on from information provided to NICE by the company in May 2021, the appraisal of Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.